(Q37836264)

24 August 2017

1 reference

title

Androgen regulation of prostate cancer: where are we now? (English)

1 reference

24 August 2017

1 reference

G Corona

1

1 reference

PubMed ID

21297383

24 August 2017

E Baldi

series ordinal

2

1 reference

PubMed ID

21297383

24 August 2017

M Maggi

series ordinal

3

1 reference

24 August 2017

4 February 2011

1 reference

Journal of Endocrinological Investigation

24 August 2017

1 reference

24 August 2017

34

1 reference

24 August 2017

3

1 reference

24 August 2017

232-243

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03347072

24 August 2017

0 references

cites work

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Abiraterone acetate for castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Persistent intraprostatic androgen concentrations after medical castration in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Recent studies on the mechanism of action of testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

5alpha-reductase isozymes and androgen actions in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Prostate cancer risk in testosterone-treated men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Update on chemoprevention for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Chemoprevention of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Identification of late-onset hypogonadism in middle-aged and elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Absence of relationship between steroid hormone levels and prostate cancer tumor grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Influence of sex hormones on cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Circulating steroid hormones and the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Hormonal predictors of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone and prostate cancer: revisiting old paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone replacement therapy after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone replacement therapy following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Endocrine aspects of male sexual dysfunctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen deprivation therapy for prostate cancer: new concepts and concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Metabolic complications of androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Cancer treatment-induced bone loss: pathophysiology and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Long-term effects of androgen deprivation therapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Insulin sensitivity during combined androgen blockade for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Testosterone, cardiovascular disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Type 2 diabetes mellitus and testosterone: a meta-analysis study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Endogenous sex hormones and metabolic syndrome in aging men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Identification of a cell of origin for human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The human PC346 xenograft and cell line panel: a model system for prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen receptor cross-talk with cell signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Neuroendocrine cells in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen receptor is a tumor suppressor and proliferator in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Targeting the stromal androgen receptor in primary prostate tumors at earlier stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Mechanisms of androgen-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03347072

TMPRSS2:ERG fusion gene and androgen-ablation therapy in prostate cancer

21 January 2018

1 reference

12 December 2020

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

1 reference

12 December 2020

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy

1 reference

12 December 2020

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

1 reference

12 December 2020

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

1 reference

12 December 2020

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

1 reference

12 December 2020

Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line.

1 reference

12 December 2020

A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy

1 reference

12 December 2020

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

1 reference

12 December 2020

Complete androgen blockade for prostate cancer: what went wrong?

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide

1 reference

12 December 2020

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

1 reference

12 December 2020

Molecular biology underlying the clinical heterogeneity of prostate cancer: an update

1 reference

12 December 2020

Pathology of benign prostatic hyperplasia

1 reference

12 December 2020

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

12 December 2020

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

12 December 2020

Androgen receptor mutations in prostate cancer.

1 reference

12 December 2020

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

1 reference

12 December 2020

Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy

1 reference

12 December 2020

Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate

1 reference

12 December 2020

Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma

1 reference

12 December 2020

Changes in body composition during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Androgen Receptor: Good Guy or Bad Guy in Prostate Cancer Invasion?

1 reference

12 December 2020

Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03347072

1 reference

24 August 2017

1 reference

PubMed ID

21297383